In this prospective phase II observational study, we plan to assess the efficacy and tolerability of caspofungin based combined anti-fungal therapy for proven or probable IFI in a group of patients received allo-HSCT transplantation with high risk of IFI: HLA matched unrelated donor or mismatched donor conditioning with ATG containing regimen or present III-IV aGVHD or extensive GVHD undergoing high-dose steroid treatment.
Patients will recieve caspofungin with either voriconazole or amphotericin B as combination therapy for fungal infection
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
55
Caspofungin: 70 mg on the first day of therapy, followed by 50 mg q.d. * All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given. * In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given.
Blood & Marrow Transplantation Center, RuiJin Hospital
Shanghai, China
RECRUITINGFavorable response rate
Time frame: 12 weeks
Overall survival
Time frame: 12 weeks, 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.